Rheumatology Medical News about ankylosing spondylitis

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Serum homocysteine level in patients with ankylosing spondylitis
Rheumatology International, 03/23/09

Baskan BM et al. - Study reports that serum homocystein (Hcy) level was higher in patients with ankylosing spondylitis (AS), especially for those receiving methotrexate (MTX) and sulfasalazine (SSZ) treatment without folic acid supplementation. Addition of folic acid to their therapy may decrease the risk of cardiovascular disease which in turn may decrease mortality in these patients.

Methods

Aim was to measure the Hcy level and study its relationship with disease activity criteria and treatment protocols in AS pts
92 AS pts and 58 healthy individuals; ESR and serum CRP were determined
Bath AS disease activity index and Bath AS functional index were calculated
Serum Hcy levels >15 µmol/l were considered as hyperhomocysteinemia

Results

Mean serum homocysteine levels were 14.40 and 12.60 µmol/l in AS pts and the control group, respectively
No significant difference between the SSZ group and the MTX/SSZ group
Significant difference between the Hcy levels of these two groups, and of the NSAID group and control group
No significant difference in mean serum Hcy level in pts with active and inactive AS

<< Previous
Use of tumor necrosis factor-α (TNF-α) antagonists...

Next >>
BMD, clinical risk factors and their combination for hip fracture...